As to the association between CRC and diabetes, meformin has also been found to be a potential drug against colorectal cancer through the regulation of AMPK and mammalian target of rapamycin (mTOR)—signaling pathway [50]. This evidence concerns the gene MTOR and colorectal carcinoma.